[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636862":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":168,"collaborators":19,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":19,"eligibilityCriteria":176,"healthyVolunteers":172,"sex":177,"minAge":178,"maxAge":179,"enrollmentInfo":180,"targetDuration":19,"studyType":183,"phases":184,"briefSummary":186,"conditions":187,"keywords":19,"overallStatus":55,"whyStopped":19,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LY4256984","EXPERIMENTAL","OL01 Substudy: LY4256984 administered intrathecally (IT)",[13],"Drug: LY4256984",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered IT",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":31,"role":27,"phone":19,"phoneExt":19,"email":32},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[34,53,70,82,98,112,126,142,156],{"facility":35,"status":36,"city":37,"state":19,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UZ Leuven","NOT_YET_RECRUITING","Leuven","3000","Belgium","BE",{"type":42,"coordinates":43},"Point",[44,45],4.70093,50.87959,{"lat":45,"lon":44},[48,50],{"name":19,"role":27,"phone":49,"phoneExt":19,"email":19},"+3216341013",{"name":51,"role":52,"phone":19,"phoneExt":19,"email":19},"Philip Van Damme","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":55,"city":56,"state":19,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"McGill University Health Centre","RECRUITING","Montreal","H4A 3J1","Canada","CA",{"type":42,"coordinates":61},[62,63],-73.58781,45.50884,{"lat":63,"lon":62},[66,68],{"name":19,"role":27,"phone":67,"phoneExt":19,"email":19},"(514) 398-8588",{"name":69,"role":52,"phone":19,"phoneExt":19,"email":19},"Angela Genge",{"facility":71,"status":36,"city":72,"state":19,"zip":73,"country":58,"countryCode":59,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Sunnybrook Research Institute","Toronto","M4N 3M5",{"type":42,"coordinates":75},[76,77],-79.39864,43.70643,{"lat":77,"lon":76},[80],{"name":81,"role":52,"phone":19,"phoneExt":19,"email":19},"Agessandro Abrahao",{"facility":83,"status":36,"city":84,"state":19,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Universitätsklinikum Schleswig-Holstein","Lübeck","23538","Germany","DE",{"type":42,"coordinates":89},[90,91],10.68729,53.86893,{"lat":91,"lon":90},[94,96],{"name":19,"role":27,"phone":95,"phoneExt":19,"email":19},"004945150043468",{"name":97,"role":52,"phone":19,"phoneExt":19,"email":19},"Julian Grosskreutz",{"facility":99,"status":36,"city":100,"state":19,"zip":101,"country":86,"countryCode":87,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Universitätsmedizin Rostock","Rostock","18147",{"type":42,"coordinates":103},[104,105],12.14049,54.0887,{"lat":105,"lon":104},[108,110],{"name":19,"role":27,"phone":109,"phoneExt":19,"email":19},"+493814949541",{"name":111,"role":52,"phone":19,"phoneExt":19,"email":19},"Andreas Hermann",{"facility":113,"status":36,"city":114,"state":19,"zip":115,"country":86,"countryCode":87,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Universitaetsklinikum Ulm","Ulm","89081",{"type":42,"coordinates":117},[118,119],9.99155,48.39841,{"lat":119,"lon":118},[122,124],{"name":19,"role":27,"phone":123,"phoneExt":19,"email":19},"0049 731 177 1201",{"name":125,"role":52,"phone":19,"phoneExt":19,"email":19},"Jochen Weishaupt",{"facility":127,"status":36,"city":128,"state":19,"zip":129,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Universitair Medisch Centrum Utrecht","Utrecht","3584 CX","Netherlands","NL",{"type":42,"coordinates":133},[134,135],5.12222,52.09083,{"lat":135,"lon":134},[138,140],{"name":19,"role":27,"phone":139,"phoneExt":19,"email":19},"+31 (0)88 755 3204",{"name":141,"role":52,"phone":19,"phoneExt":19,"email":19},"Leonard H. Berg",{"facility":143,"status":36,"city":144,"state":19,"zip":145,"country":146,"countryCode":147,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Hospital Universitari de Bellvitge","L'Hospitalet de Llobregat","08907","Spain","ES",{"type":42,"coordinates":149},[150,151],2.10028,41.35967,{"lat":151,"lon":150},[154],{"name":155,"role":52,"phone":19,"phoneExt":19,"email":19},"MONICA POVEDANO PANADES",{"facility":157,"status":36,"city":158,"state":19,"zip":159,"country":146,"countryCode":147,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Hospital Universitari i Politecnic La Fe","Valencia","46026",{"type":42,"coordinates":161},[162,163],-0.37966,39.47391,{"lat":163,"lon":162},[166],{"name":167,"role":52,"phone":19,"phoneExt":19,"email":19},"Juan Vazquez-Costa",{"type":169,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100636862","phase-1-a-master-protocol-olmp-a-study-of-ly4256984-in-participants-with-amyotrophic-lateral-sclerosis-als-100636862",false,"NCT07571200","A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)","A Master Protocol for Open-Label Extension Studies to Evaluate the Long-Term Safety and Tolerability of Interventions in Various Stages of Clinical Development in Participants With Amyotrophic Lateral Sclerosis","Participants must meet eligibility criteria below. Additional criteria are specified in the substudy to which the participant will enroll.\n\nInclusion Criteria:\n\n* Have completed an eligible parent study, as determined by the investigator. Eligible parent studies will be defined by the sponsor but will be clinical studies designed to evaluate a study intervention for the treatment of ALS.\n\n  * Note 1: To be considered a \"completer\" of a parent study, the participant must finish the main treatment period\u002Fphase of the parent study as well as any off-treatment period\u002Fphase as described in the parent study's protocol.\n  * Note 2: Visits missed in a parent study will have no impact on the completer status of a potential participant.\n\nExclusion Criteria:\n\n* During the parent study, the participant permanently or temporarily discontinued the investigational medicinal product (IMP), such that restarting the IMP would pose an unacceptable risk to the participant's safety, in the opinion of the investigator.\n* During the parent study, the participant experienced extreme ALS disease progression (for example, permanent mechanical ventilation) that poses an unacceptable risk to the participant's safety in the opinion of the investigator.\n* During the parent study, the participant developed an unresolved SAE or a medical illness (other than ALS) that, in the opinion of the investigator, precludes either continued exposure to an IMP or participation in study procedures due to an unacceptable risk to the participant's safety.","ALL","18 Years","80 Years",{"count":181,"type":182},32,"ESTIMATED","INTERVENTIONAL",[185],"PHASE1","Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group: Sporadic Amyotrophic Lateral Sclerosis OL01 (NCT07571174). The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.",[188],"Amyotrophic Lateral Sclerosis","2026-06-19",{"date":191,"type":192},"2026-06-24","ACTUAL",{"date":194,"type":192},"2026-05-14",{"date":196,"type":182},"2029-06",{"name":5,"class":6},9]